Wang W, He L, Lin T, Xiang F, Wu Y, Zhou F
Front Oncol. 2025; 15:1522273.
PMID: 39949739
PMC: 11821653.
DOI: 10.3389/fonc.2025.1522273.
Lossius-Cott C, Annoh A, Bens M, Nietzsche S, Hoffmann B, Figge M
JBMR Plus. 2025; 9(3):ziae173.
PMID: 39906260
PMC: 11788565.
DOI: 10.1093/jbmrpl/ziae173.
Zhu C, Stiehl T
Sci Rep. 2024; 14(1):25060.
PMID: 39443599
PMC: 11500015.
DOI: 10.1038/s41598-024-75429-7.
Su C, Kim S, Wang C, Kirsch D, Monjazeb A
Semin Radiat Oncol. 2024; 34(2):243-257.
PMID: 38508788
PMC: 11216412.
DOI: 10.1016/j.semradonc.2024.01.001.
Sung P, Selvam M, Riedel S, Xie H, Bryant K, Manning B
Leukemia. 2024; 38(2):291-301.
PMID: 38182819
PMC: 11141246.
DOI: 10.1038/s41375-023-02131-4.
The interplay of FLT3 and CXCR4 in acute myeloid leukemia: an ongoing debate.
Klement L, Drube J
Front Oncol. 2023; 13:1258679.
PMID: 37849810
PMC: 10577206.
DOI: 10.3389/fonc.2023.1258679.
Blockade of de novo pyrimidine biosynthesis triggers autophagic degradation of oncoprotein FLT3-ITD in acute myeloid leukemia.
Ma H, Cui J, Liu Z, Fang W, Lu S, Cao S
Oncogene. 2023; 42(45):3331-3343.
PMID: 37752234
DOI: 10.1038/s41388-023-02848-7.
Optimization of Tyrosine Kinase Inhibitor-Loaded Gold Nanoparticles for Stimuli-Triggered Antileukemic Drug Release.
Tatar A, Nagy-Simon T, Tigu A, Tomuleasa C, Boca S
J Funct Biomater. 2023; 14(8).
PMID: 37623644
PMC: 10455807.
DOI: 10.3390/jfb14080399.
How ITD Insertion Sites Orchestrate the Biology and Disease of FLT3-ITD-Mutated Acute Myeloid Leukemia.
Haage T, Schraven B, Mougiakakos D, Fischer T
Cancers (Basel). 2023; 15(11).
PMID: 37296951
PMC: 10251898.
DOI: 10.3390/cancers15112991.
A novel lncRNA SNHG29 regulates EP300- related histone acetylation modification and inhibits FLT3-ITD AML development.
Liu S, Zhou J, Ye X, Chen D, Chen W, Lin Y
Leukemia. 2023; 37(7):1421-1434.
PMID: 37157016
DOI: 10.1038/s41375-023-01923-y.
Targeting Proliferation Signals and the Cell Cycle Machinery in Acute Leukemias: Novel Molecules on the Horizon.
Luserna di Rora A, Jandoubi M, Martinelli G, Simonetti G
Molecules. 2023; 28(3).
PMID: 36770891
PMC: 9920029.
DOI: 10.3390/molecules28031224.
PCW-A1001, AI-assisted design approach to design a selective inhibitor for FLT-3(D835Y) in acute myeloid leukemia.
Jang S, Sivakumar D, Mudedla S, Choi J, Lee S, Jeon M
Front Mol Biosci. 2022; 9:1072028.
PMID: 36504722
PMC: 9732455.
DOI: 10.3389/fmolb.2022.1072028.
Disrupting PTPRJ transmembrane-mediated oligomerization counteracts oncogenic receptor tyrosine kinase FLT3 ITD.
Schwarz M, Rizzo S, Paz W, Kresinsky A, Thevenin D, Muller J
Front Oncol. 2022; 12:1017947.
PMID: 36452504
PMC: 9701752.
DOI: 10.3389/fonc.2022.1017947.
FLT3 inhibitors as maintenance therapy post allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia patients with FLT3 mutations: A meta-analysis.
Fei X, Zhang S, Gu J, Wang J
Cancer Med. 2022; 12(6):6877-6888.
PMID: 36411731
PMC: 10067110.
DOI: 10.1002/cam4.5480.
Activating Mutation in the Receptor Tyrosine Kinase FLT3 with Clinicopathological Relevance in Canine Mast Cell Tumors.
Manachai N, Rattanapinyopituk K, Fonghem P, Phoomvuthisarn P, Nakahata S, Morishita K
Vet Med Int. 2022; 2022:9509900.
PMID: 36072760
PMC: 9441376.
DOI: 10.1155/2022/9509900.
Targeting Acute Myeloid Leukemia with Venetoclax; Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination Therapies.
Griffioen M, De Leeuw D, Janssen J, Smit L
Cancers (Basel). 2022; 14(14).
PMID: 35884517
PMC: 9318140.
DOI: 10.3390/cancers14143456.
"FLipping" the Story: FLT3-Mutated Acute Myeloid Leukemia and the Evolving Role of FLT3 Inhibitors.
Knight T, Edwards H, Meshinchi S, Taub J, Ge Y
Cancers (Basel). 2022; 14(14).
PMID: 35884458
PMC: 9315611.
DOI: 10.3390/cancers14143398.
FLT3-targeted treatment for acute myeloid leukemia.
Arai Y, Chi S, Minami Y, Yanada M
Int J Hematol. 2022; 116(3):351-363.
PMID: 35532877
DOI: 10.1007/s12185-022-03374-0.
mutations in acute myeloid leukemia: a review focusing on clinically applicable drugs.
Ahn J, Kim H
Blood Res. 2022; 57(S1):32-36.
PMID: 35483923
PMC: 9057665.
DOI: 10.5045/br.2022.2022017.
FLT3-inhibitor therapy for prevention and treatment of relapse after allogeneic hematopoietic cell transplantation.
Biavasco F, Zeiser R
Int J Hematol. 2022; 116(3):341-350.
PMID: 35460465
PMC: 9392688.
DOI: 10.1007/s12185-022-03352-6.